Acumen Pharmaceuticals, Inc. (ABOS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+56.7%

$0.38

vs $0.24 price

Levered DCF

$0.37

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-11.67

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-1.06×	-1.01×	-3.56×	-5.09×	-2.57×	-77.31×	-100.5×
P/B	1.81×	0.57×	0.7×	1.16×	1.15×	-30.98×	-50.43×
P/S	0×	0×	0×	0×	0×	401.05×	339.36×
EV / EBITDA	-0.9×	-0.99×	-2.86×	-2.09×	-1.36×	-67.26×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	-456.9%	-405.4%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	-551.0%	-459.9%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	-510.1%	-465.9%
Current ratio	4.07×	6.46×	19.01×	23.08×	38.6×	6.98×	5.35×
Debt / equity	0.44×	0.16×	0.11×	0×	0×	0×	0×
Interest coverage	-29.32×	-28.03×	-105.23×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-172.3%	-56.3%	-19.6%	-22.7%	-44.7%	39.4%	69.2%
Return on invested capital	-121.7%	-53.9%	-20.5%	-24.0%	-8.7%	-20.8%	-130.5%
Return on assets	-98.8%	-42.8%	-16.9%	-21.8%	-43.7%	-16.5%	-108.0%
Free cash flow yield	-90.5%	-83.5%	-23.1%	-16.1%	-7.0%	-1.3%	-1.2%
Earnings yield	-95.0%	-99.1%	-28.1%	-19.5%	-38.9%	-1.3%	-1.4%
Enterprise value	$105.1M	$97.3M	$147.8M	$89.3M	$136.5M	$532.1M	$569.3M
Net debt / EBITDA	0.19×	0.06×	0.74×	3.05×	1.21×	5.53×	0×
Cash conversion cycle (days)	0	0	0	0	-32	3	-3